Cancer Research Technology
Log in Register
Menu
Search
Monoclonal Antibodies

Anti-PASD1 [2ALCC136]

Invented by Prof Alison Banham from University of Oxford , Karen Pulford from University of Oxford
Invented at University of Oxford
  • Datasheet
  • Inventor Info
Print

Info

Image thumbnail for Anti-PASD1 [2ALCC136]
Image thumbnail for Anti-PASD1 [2ALCC136]
Image thumbnail for Anti-PASD1 [2ALCC136]
Image thumbnail for Anti-PASD1 [2ALCC136]
Add an image
PASD1 Schematic exon structure of the PASD1 gene and the regions used to generate immunogens for the production of PASD1 monoclonal antibodies.
HC FFPE Staining of formalin fixed and paraffin embedded human tissues with the PASD1-1 2ALCC136 antibody. Testis shows strong nuclear expression in a subpopulation of spermatogonia near the basal membrane in testicular tubules. Tonsil, like most normal human tissues shows no PASD1 labelling. Nuclear PASD1 protein was detectable in the lung cancer cell line NCI-H1299. The MR12 mouse monoclonal antibody was used as a negative control to demonstrate the specificity of PASD1 staining.
IHC frozen Staining of 293T cells transiently transfected with cDNA expressing the long isoform of PASD1. PASD1-1 clone 2ALCC136 did not stain untransfected 293T cells; MR12 was used as a control antibody to detect any non-specific background.
Western Blotting PASD1 silencing with three independent PASD1 siRNAs was performed to validate the identity of the endogenous protein detected by Western Blotting in BT-20 breast cancer cells. Controls from left to right are untreated, mock siRNA, control siRNA. Experiments in other cell types have given similar results. There may be some variability in the m.wt. of PASD1, 100-150kDa.
Add an image
Image thumbnail for Anti-PASD1 [2ALCC136] Image thumbnail for Anti-PASD1 [2ALCC136] Image thumbnail for Anti-PASD1 [2ALCC136] Image thumbnail for Anti-PASD1 [2ALCC136]
Catalogue Number 152546
Applications IHC IF WB
Antigen/Gene or Protein Targets PAS domain-containing protein 1 (PASD1), Per Arnt Sim domain 1
Reactivity Human
Relevance Cancer testis antigens (CTAs) such as PASD1 represent attractive immunotherapy targets, having normal tissue expression that is testis restricted and commonly widespread expression in tumours. PASD1 was originally identified as a target of anti-tumour immune responses in patients with aggressive diffuse large B-cell lymphoma. Subsequent studies have identified PASD1 expression in myeloma patients (both pre- and post-treatment) and in a broad range of solid tumours, 65/160 samples (41%) from 9 histological types. Interestingly a new immune response to PASD1 was detected in a melanoma patient who exhibited a systemic immune response to palliative radiotherapy with regression of nonirradiated lesions, the abscopal effect. Delivery of immunogenic PASD1 peptides using a DNA vaccine was able to induce immune responses in preclinical models, demonstrating its potential for immunotherapy applications.

There is relatively little information regarding the function of many CTAs. However, recently PASD1 has been identified as a novel regulator of the circadian clock that interacts with the CLOCK:BMAL1 complex to repress its transcriptional activation. This suggests that PASD1 may contribute to oncogenic transformation through the suppression of circadian rhythms.
Host Mouse
Immunogen GST-PASD1 recombinant protein containing 195-474 aas of PASD1. Region is common to PASD1a and PASD1b proteins.
Positive Control PASD-1 transfected cells and testis; BT-20 and NCI-H1299 carcinoma lines (negative control: MDA-MB-231, tonsil)
Subclass IgG
Molecular Weight (kDa) 100
Myeloma Used NS0
Notes PASD1-1 recognizes the recombinant protein (aa 195–474) present in both PASD1_v1 and PASD1_v2 proteins. Antibody PASD1-1 stains nuclei of a subpopulation of spermatogonia near the basal membrane in testicular tubules, with decreasing intensity of labeling with maturity. IHC stainings may be performed on FFPE and cryostat preparations of cells and tissues.
Subclass is IgG2a/IgM mixture despite repeated re-cloning.
In WB, expected MW is 87.5 kDa/72.5 kDa, observed MW is ~100 kDa.

Recognises both PASD1a and PASD1b proteins.
Research Area Epigenetics & Nuclear Signalling

References

There are 20 reference entries for this reagent.

View All References

References: 20 entries

Boullosa et al. 2018. Oncotarget. 9(3):3853-3866. PMID: 29423088.

IHC

View  

Identification of survivin as a promising target for the immunotherapy of adult B-cell acute lymphoblastic leukemia.

Europe PMC ID: 29423088

View  

Brooks et al. 2015. PLoS One. 10(10):e0140483. PMID: 26492414.

IF

View  

Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis.

Europe PMC ID: 26492414

View  

Khan et al. 2015. Biomark Cancer. 7:31-8. PMID: 26327782.

IHC

View  

Infrequent Expression of the Cancer-Testis Antigen, PASD1, in Ovarian Cancer.

Europe PMC ID: 26327782

View  

Michael et al. 2015. Mol Cell. 58(5):743-54. PMID: 25936801.

IHC WB

View  

Cancer/Testis Antigen PASD1 Silences the Circadian Clock.

Europe PMC ID: 25936801

View  

Hardwick et al. 2013. Cancer Immun. 13:16. PMID: 23882161.

IHC

View  

An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide.

Europe PMC ID: 23882161

View  

Ait-Tahar et al. 2011. Haematologica. 96(1):78-86. PMID: 20851862.

IHC

View  

Joseph-Pietras et al. 2010. Leukemia. 24(11):1951-9. PMID: 20861911.

IHC WB

View  

DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma.

Europe PMC ID: 20861911

View  

CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma.

Europe PMC ID: 20851862

View  

Ait-Tahar et al. 2009. Br J Haematol. 146(4):396-407. PMID: 19552722.

IHC

View  

Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma.

Europe PMC ID: 19552722

View  

Cooper et al. 2006. Leukemia. 20(12):2172-4. PMID: 17024112.

IHC WB

View  

Sahota et al. 2006. Blood. 108(12):3953-5. PMID: 17114574.

IHC

View  

PASD1 is a potential multiple myeloma-associated antigen.

Europe PMC ID: 17114574

View  

PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy.

Europe PMC ID: 17024112

View  

Add a reference

References: 20 entries

Boullosa et al. 2018. Oncotarget. 9(3):3853-3866. PMID: 29423088.

IHC

View  

Identification of survivin as a promising target for the immunotherapy of adult B-cell acute lymphoblastic leukemia.

View  

Brooks et al. 2015. PLoS One. 10(10):e0140483. PMID: 26492414.

IF

View  

Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis.

View  

Khan et al. 2015. Biomark Cancer. 7:31-8. PMID: 26327782.

IHC

View  

Infrequent Expression of the Cancer-Testis Antigen, PASD1, in Ovarian Cancer.

View  

Michael et al. 2015. Mol Cell. 58(5):743-54. PMID: 25936801.

IHC WB

View  

Cancer/Testis Antigen PASD1 Silences the Circadian Clock.

View  

Hardwick et al. 2013. Cancer Immun. 13:16. PMID: 23882161.

IHC

View  

An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide.

View  

Ait-Tahar et al. 2011. Haematologica. 96(1):78-86. PMID: 20851862.

IHC

View  

Joseph-Pietras et al. 2010. Leukemia. 24(11):1951-9. PMID: 20861911.

IHC WB

View  

DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma.

View  

CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma.

View  

Ait-Tahar et al. 2009. Br J Haematol. 146(4):396-407. PMID: 19552722.

IHC

View  

Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma.

View  

Cooper et al. 2006. Leukemia. 20(12):2172-4. PMID: 17024112.

IHC WB

View  

Sahota et al. 2006. Blood. 108(12):3953-5. PMID: 17114574.

IHC

View  

PASD1 is a potential multiple myeloma-associated antigen.

View  

PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy.

View  

Add a reference

Inventor Information